Search

Search Constraints

You searched for: Author/Creator Berton, Dominique

Search Results

1. 2022-RA-1088-ESGO Chitinase response after 3 cycles of chemotherapy as a promising marker of chemosensitivity an ancillary analysis of the GINECO-ENGOT EWOC-1 trial. (20th October 2022)

2. 2022-RA-1134-ESGO First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort. (20th October 2022)

3. 2022-RA-1144-ESGO Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study. (20th October 2022)

4. 2022-RA-605-ESGO Long term quality of life after chemotherapy among rare ovarian cancer survivors: the national gineco case-control Vivrovaire Rare Tumors study. (20th October 2022)

5. 2022-RA-823-ESGO FOXL2 mutation detection in circulating tumor DNA of adult granulosa cell tumors as a potential biomarker for disease monitoring from the randomized ALIENOR trial, a GINECO study. (20th October 2022)

6. 2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial. (20th October 2022)

7. 6/#455 Management of immune-related adverse events in patients with solid tumors treated with dostarlimab in the garnet study. (4th December 2022)

9. O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial. (4th December 2022)

10. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Issue 6 (27th January 2022)